(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) rose by a staggering 33.2% in 10 sessions from €0.1 to €0.13 at 17:08 EST on Wednesday, after two sequential sessions in a row of gains. BEL 20 is sliding 0.11% to €3,684.79, following the last session’s downward trend.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.4.
More news about BIOSENIC (BIOS.BR).
